Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Praxis Precision Medicines ( (PRAX) ).
On June 26, 2025, Praxis Precision Medicines, Inc. held its Annual Meeting of Stockholders, where key decisions were made. Stockholders elected two Class II directors, ratified the appointment of Ernst & Young LLP as the independent accounting firm, and approved executive compensation on a non-binding basis. These outcomes reflect the company’s ongoing governance and operational strategies, potentially impacting its future direction and stakeholder relations.
The most recent analyst rating on (PRAX) stock is a Buy with a $114.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.
Spark’s Take on PRAX Stock
According to Spark, TipRanks’ AI Analyst, PRAX is a Neutral.
Praxis Precision Medicines is facing substantial financial and valuation challenges, which significantly impact its stock score. However, positive corporate developments and some technical support offer potential upside. The company’s ability to improve its financial health and successfully advance its pipeline will be crucial for future performance.
To see Spark’s full report on PRAX stock, click here.
More about Praxis Precision Medicines
Praxis Precision Medicines, Inc. operates in the pharmaceutical industry, focusing on developing treatments for central nervous system disorders. The company is involved in creating precision medicines aimed at addressing neurological conditions.
Average Trading Volume: 396,580
Technical Sentiment Signal: Sell
Current Market Cap: $882.6M
Find detailed analytics on PRAX stock on TipRanks’ Stock Analysis page.